Furthermore, a very interesting study found that chimeric antigen receptor T cell (CAR-T) therapy, combined with the blockade of the AIM2 inflammasome or α1-adrenergic receptor (α1-AR), involved in both AIM2 activation and overexpression, may relieve IL-1β-related toxic side effects of CAR-T therapy and ensure anti-tumor effects of the treatment [61]. This evidence concerns the gene AIM2 and neoplasm.